What Is a Molecular Tumour Board, and Why Does a Multidisciplinary Team Plan Better?

What is a molecular tumour board?

If you are being treated abroad and have just received a genomic report running to dozens of pages, the first two questions are usually the same: how do I read this, and which lines actually matter? A molecular tumour board exists to answer exactly those questions. This article, prepared by the YOUNIFY Clinic medical team, explains what a board is, who sits at the table, what it reviews and why several sets of eyes produce a steadier plan than one. For the wider picture, you may also want to read what precision oncology is.

A molecular tumour board (MTB) is a meeting in which clinicians and scientists from several disciplines review one patient's tumour genomic results together with the whole clinical record, and then issue written recommendations back to the treating physician and the patient.

What separates an MTB from an ordinary consultation is the starting point. The board begins with the molecular report and then layers everything else on top of it — pathology, imaging, treatment history, performance status, comorbidities, current medications and what matters to the patient. The output is therefore not an answer read straight off a report, but a recommendation weighed against that person's real circumstances.

An MTB does not prescribe. Its conclusions have the status of advice. The decision stays with the patient and the treating physician, and this article is written to help you ask your own oncologist sharper questions rather than to move your care anywhere.

Who sits at the table

The exact composition varies by institution and by case, but the principle is constant: bring the people who each hold a different part of the same case into one room, so the information is read together rather than one document at a time.

Other disciplines are invited when the case calls for it — for example the physician managing a comorbidity that constrains drug choice.

What the board reviews, step by step

A well-run board follows a sequence that builds from the basics towards a conclusion. It does not open the genomic report and start looking for drug names. The order itself is what prevents decisions being made on incomplete information.

• Clinical review — diagnosis, stage, prior treatments and how the disease responded to them, performance status, comorbidities, and the goals the patient has said matter most.
• Sample and assay quality — did the specimen contain enough tumour cells, was it tissue or blood, when was it taken, and before or after which line of treatment? This is discussed further in liquid biopsy and ctDNA testing.
• Tiering the findings — separating alterations with solid supporting evidence from those with limited evidence and from variants of uncertain significance, using the tiering frameworks in clinical use. The report format itself is explained in comprehensive genomic profiling.
• Practical feasibility — is the option accessible, is there a contraindication in this patient, does it interact with current medication, and is the patient in a position to tolerate the monitoring it requires? The drug classes involved are described in how targeted therapy and immunotherapy work.
• All options, not only those suggested by the report — including continuing the current standard treatment, considering an appropriate clinical study, and running supportive care alongside.
• A written recommendation — with the reasoning and the remaining uncertainties recorded, sent back to the treating physician and explained to the patient and family.

One point deserves stating plainly: the molecular tests a board reviews are ordered for people who already have a cancer diagnosis. They are not a screening test for people who do not.

Why a multidisciplinary team improves planning

A molecular report is easy to misread alone. Several disciplines reading it together place each finding in the right context, which reduces both the risk of overlooking something useful and the risk of over-weighting something that is not yet supported.

• It keeps variants of uncertain significance in proportion. A single report often lists a great many lines; a molecular scientist helps identify which of them can actually inform a decision.
• It connects the report to the body in front of you. A matched target may still be unusable in someone with organ-function limits or a specific contraindication.
• It checks interactions. Many people with cancer already take several medicines, and a pharmacist in the room prevents problems that are avoidable.
• It verifies sample quality. A specimen with low tumour content can produce a false negative, and a pathologist flags that at the outset rather than months later.
• It reflects the disease as it is today. The radiologist describes how things are changing, which affects how urgent a decision needs to be.
• It handles findings that touch the family, setting out confirmatory testing and counselling where an inherited component is suspected.
• It records the reasoning, which matters when the plan is revisited later or when care is handed between hospitals or countries.

Just as importantly, a board confirms what remains available when not every tumour carries a genomic alteration for which a targeted drug exists — so a report without a matched target becomes a documented conclusion rather than a dead end.

Who this process may suit

Broadly, a molecular tumour board suits people who already hold a tumour genomic report, or are about to have one, and who have a clinical question that benefits from more than one perspective. It is not a necessary step for every person with cancer.

• People who have just received a tumour genomic report and want it interpreted systematically rather than line by line.
• People with a rare cancer, a cancer of unknown primary, or a case where the standard pathway is not straightforward.
• People whose disease has progressed through several lines of treatment and who are weighing what comes next.
• People with multiple comorbidities or a long medication list, where drug selection has to account for several constraints at once.
• People who want a molecular second opinion to discuss with the oncologist who is already treating them.
• People travelling from abroad who want everything reviewed in one consolidated round before they fly home.

If you are travelling, it helps to assemble the documentation before departure: the pathology report and any special stains, imaging on disc or via a shared link, a treatment timeline with dates and responses, a current medication list, and recent blood results. A complete file is what makes a single review round possible.

Limitations you should know

A board makes a decision better informed. It does not tell anyone in advance how treatment will turn out, and it has limits worth agreeing on from the start.

• Its conclusions are recommendations, not instructions. The final decision rests with you and your treating physician; please decide together with them and do not adjust or stop your current treatment on your own.
• Not every tumour carries a genomic alteration for which a targeted drug exists. In many cases the board's recommendation is to continue the current standard treatment, and that is an evidence-based conclusion rather than a disappointing one.
• Some recommendations turn out not to be practicable — because of the patient's condition, indications, or the availability of that option at the time.
• The quality of the conclusion depends on the quality of what goes in. An inadequate sample or an incomplete clinical record limits what any board can say.
• The process takes time to assemble documents and schedule the meeting. Where a decision is urgent, the medical team may advise starting standard treatment while the review is arranged.
• A board cannot predict how an individual will respond. Outcomes vary from person to person.

Costs depend on which tests and which plan are involved. The medical team assesses and explains all costs before anything begins.

What to expect at YOUNIFY

At YOUNIFY Clinic, bringing a case to a multidisciplinary discussion is built into the care pathway from the beginning rather than offered on request, because a molecular result should not become a treatment decision on its own.

• Collect the documentation — pathology, special stains, imaging, treatment history and responses, current medications, and recent blood results.
• Check completeness before the meeting — the coordinator will tell you if something material is missing, so the discussion is not built on a partial record.
• Bring the case to the multidisciplinary meeting — reviewed in the sequence described above, with the reasoning behind each recommendation recorded.
• Explain the outcome to the patient and family — the available options, the trade-offs of each, what remains uncertain, and what needs following up.
• Coordinate the agreed plan — where the plan calls for chemotherapy, radiotherapy or cancer surgery, the medical team arranges a coordinated referral to a partner facility and forwards the complete record.
• Revisit when things change — for example if the disease progresses or new results arrive.

If you already hold a tumour genomic report and would like it reviewed systematically before your next appointment at home, you can read how the pathway works on our precision oncology service page, or message the team on WhatsApp to ask which documents to prepare. Nothing about a review requires you to change where you are being treated — the written summary is yours to take back to your own oncologist, in your own time.